
- /
- Supported exchanges
- / US
- / ANRO.NYSE
Alto Neuroscience, Inc. (ANRO NYSE) stock market data APIs
Alto Neuroscience, Inc. Financial Data Overview
Alto Neuroscience, Inc. operates as a clinical-stage biopharmaceutical company in the United States. The company's product pipeline includes ALTO-100, which is in Phase 2b clinical trial for the treatment of patients with bipolar depression (BPD). It also develops ALTO-300, a small molecule melatonergic agonist and serotonergic antagonist with antidepressant properties, which is in Phase 2b clinical trial to treat patients with major depressive disorder (MDD); ALTO-101, a novel small molecule phosphodiesterase 4 inhibitor that is in Phase 2 proof-of-concept (POC) trial for the treatment of cognitive impairment associated with schizophrenia; ALTO-203, a novel small-molecule histamine H3 receptor inverse agonist, which is in Phase 2 POC trial to treat patients with MDD and higher levels of anhedonia; and ALTO-202, an investigational orally bioavailable antagonist of the GluN2B subunit of the NMDA receptor that is in Phase 1 clinical trial for the treatment of MDD. The company was incorporated in 2019 and is headquartered in Mountain View, California.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Or get access to advanced financial data starting only $19.99
Get Alto Neuroscience, Inc. data using free add-ons & libraries
Get Alto Neuroscience, Inc. Fundamental Data
Alto Neuroscience, Inc. Fundamental data includes:
- Net Revenue:
- EBITDA: -69 324 000
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-05-15
- EPS/Forecast: -0.6214
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Alto Neuroscience, Inc. News

William Blair reiterates outperform rating on Alto Neuroscience stock
Investing.com - William Blair maintained its outperform rating on Alto Neuroscience (NYSE:ANRO) stock on Thursday following mixed clinical trial results for the company’s ALTO-203 drug candidate. ...


Alto Neuroscience stock holds Buy rating at Stifel despite mixed trial data
Investing.com - Stifel maintained its Buy rating and $10.00 price target on Alto Neuroscience (NYSE:ANRO) Thursday following the company’s announcement of Phase 2 proof-of-concept results for its ...

Regeneron makes obesity push; Atai, Alto ink brain drug deals
This story was originally published on BioPharma Dive. To receive daily news and insights, subscribe to our free daily BioPharma Dive newsletter. Today, a brief rundown of news involving Regeneron an...

15 Healthiest Countries in Asia
In this article, we will be taking a look at the 15 Healthiest Countries in Asia. You can skip our detailed analysis on the health market and directly head to the 5 Healthiest Countries in Asia. Grow...
Or get access to advanced financial data starting only $19.99
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.